Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial.

MLA

Bressler, Neil M., et al. “Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial.” JAMA Ophthalmology, vol. 136, no. 3, Mar. 2018, pp. 257–69. EBSCOhost, https://doi.org/10.1001/jamaophthalmol.2017.6565.

APA

Bressler, N. M., Beaulieu, W. T., Glassman, A. R., Blinder, K. J., Bressler, S. B., Jampol, L. M., Melia, M., & Wells, J. A., 3rd. (2018). Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial. JAMA Ophthalmology, 136(3), 257–269. https://doi.org/10.1001/jamaophthalmol.2017.6565

Chicago

Bressler, Neil M, Wesley T Beaulieu, Adam R Glassman, Kevin J Blinder, Susan B Bressler, Lee M Jampol, Michele Melia, and John A Wells 3rd. 2018. “Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial.” JAMA Ophthalmology 136 (3): 257–69. doi:10.1001/jamaophthalmol.2017.6565.